

FORM PTO-1390 (REV. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 082370-000000US
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Unassigned 10/019832
INTERNATIONAL APPLICATION NO. PCT/JP00/02733	INTERNATIONAL FILING DATE April 26, 2000	PRIORITY DATE CLAIMED April 27, 1999	
TITLE OF INVENTION Pollen Allergy-Related Gene 513			
APPLICANT(S) FOR DO/EO/US Nagasu et al.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 36 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 37(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 			
Items 11 to 20 below concern document(s) or information included:			
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 36 U.S.C. 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: 			
Express Mail Label # EL525748597US			
Application Data Sheet			

I/S/ Application no. (if known, see 37 CFR 1.5) ~~~~~ Unassigned 10/019832		INTERNATIONAL APPLICATION NO. PCT/JP00/02733		ATTORNEY'S DOCKET NUMBER 082370-000000US																																																																																																																	
21. <input checked="" type="checkbox"/> - The following fees are submitted:				CALCULATIONS PTO USE ONLY																																																																																																																	
BASIC NATIONAL FEE (37 CFR 1.492(A) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search report prepared by the EPO or JPO\$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)(4)\$100.00				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 2px;"> ENTER APPROPRIATE BASIC FEE AMOUNT = Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). </td> <td style="width: 50%; padding: 2px;"> \$890 </td> </tr> <tr> <td style="padding: 2px;"> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;">\$</th> </tr> <tr> <td>Total claims</td> <td>20 - 20 =</td> <td></td> <td>x \$18.00</td> <td>\$</td> </tr> <tr> <td>Independent claims</td> <td>3 - 3 =</td> <td></td> <td>x \$84.00</td> <td>\$</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ 280.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$890</td> </tr> <tr> <td colspan="4"> <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. </td> <td>+</td> </tr> <tr> <td colspan="4">SUBTOTAL =</td> <td>\$890</td> </tr> <tr> <td colspan="4"> Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFT 1.492(f)). </td> <td>\$</td> </tr> <tr> <td colspan="4">TOTAL NATIONAL FEE =</td> <td>\$890</td> </tr> <tr> <td colspan="4"> Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property </td> <td>+</td> </tr> <tr> <td colspan="4">TOTAL FEES ENCLOSED =</td> <td>\$890</td> </tr> <tr> <td colspan="4"></td> <td>Amount to be refunded:</td> <td>\$</td> </tr> <tr> <td colspan="4"></td> <td>charged:</td> <td>\$</td> </tr> </table> </td> </tr> <tr> <td colspan="4" style="padding: 2px;"> a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed. </td> <td colspan="2" rowspan="4" style="padding: 2px;"></td> </tr> <tr> <td colspan="4" style="padding: 2px;"> b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 20-1430 in the amount of \$_____ to cover the above fees. </td> </tr> <tr> <td colspan="4" style="padding: 2px;"> c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 20-1430. A duplicate copy of this sheet is enclosed. </td> </tr> <tr> <td colspan="4" style="padding: 2px;"> d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. </td> </tr> <tr> <td colspan="6" style="padding: 2px;"> NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status. </td> </tr> <tr> <td colspan="6" style="padding: 2px;"> SEND ALL CORRESPONDENCE TO: </td> </tr> <tr> <td colspan="6" style="padding: 2px;"> Joe Liebeschuetz Townsend and Townsend and Crew LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111 </td> </tr> <tr> <td colspan="6" style="padding: 2px; text-align: right;"> <div style="display: flex; align-items: center;"> <div> SIGNATURE Joe Liebeschuetz NAME 37.505 REGISTRATION NUMBER </div> </div> </td> </tr> </table>		ENTER APPROPRIATE BASIC FEE AMOUNT = Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$890	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;">\$</th> </tr> <tr> <td>Total claims</td> <td>20 - 20 =</td> <td></td> <td>x \$18.00</td> <td>\$</td> </tr> <tr> <td>Independent claims</td> <td>3 - 3 =</td> <td></td> <td>x \$84.00</td> <td>\$</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ 280.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$890</td> </tr> <tr> <td colspan="4"> <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. </td> <td>+</td> </tr> <tr> <td colspan="4">SUBTOTAL =</td> <td>\$890</td> </tr> <tr> <td colspan="4"> Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFT 1.492(f)). </td> <td>\$</td> </tr> <tr> <td colspan="4">TOTAL NATIONAL FEE =</td> <td>\$890</td> </tr> <tr> <td colspan="4"> Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property </td> <td>+</td> </tr> <tr> <td colspan="4">TOTAL FEES ENCLOSED =</td> <td>\$890</td> </tr> <tr> <td colspan="4"></td> <td>Amount to be refunded:</td> <td>\$</td> </tr> <tr> <td colspan="4"></td> <td>charged:</td> <td>\$</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	20 - 20 =		x \$18.00	\$	Independent claims	3 - 3 =		x \$84.00	\$	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ 280.00	TOTAL OF ABOVE CALCULATIONS =				\$890	<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+	SUBTOTAL =				\$890	Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFT 1.492(f)).				\$	TOTAL NATIONAL FEE =				\$890	Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	TOTAL FEES ENCLOSED =				\$890					Amount to be refunded:	\$					charged:	\$	a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.						b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 20-1430 in the amount of \$_____ to cover the above fees.				c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 20-1430 . A duplicate copy of this sheet is enclosed.				d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.						SEND ALL CORRESPONDENCE TO:						Joe Liebeschuetz Townsend and Townsend and Crew LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111						<div style="display: flex; align-items: center;"> <div> SIGNATURE Joe Liebeschuetz NAME 37.505 REGISTRATION NUMBER </div> </div>					
ENTER APPROPRIATE BASIC FEE AMOUNT = Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$890																																																																																																																				
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;">\$</th> </tr> <tr> <td>Total claims</td> <td>20 - 20 =</td> <td></td> <td>x \$18.00</td> <td>\$</td> </tr> <tr> <td>Independent claims</td> <td>3 - 3 =</td> <td></td> <td>x \$84.00</td> <td>\$</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ 280.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$890</td> </tr> <tr> <td colspan="4"> <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. </td> <td>+</td> </tr> <tr> <td colspan="4">SUBTOTAL =</td> <td>\$890</td> </tr> <tr> <td colspan="4"> Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFT 1.492(f)). </td> <td>\$</td> </tr> <tr> <td colspan="4">TOTAL NATIONAL FEE =</td> <td>\$890</td> </tr> <tr> <td colspan="4"> Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property </td> <td>+</td> </tr> <tr> <td colspan="4">TOTAL FEES ENCLOSED =</td> <td>\$890</td> </tr> <tr> <td colspan="4"></td> <td>Amount to be refunded:</td> <td>\$</td> </tr> <tr> <td colspan="4"></td> <td>charged:</td> <td>\$</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA			RATE	\$	Total claims	20 - 20 =		x \$18.00	\$	Independent claims	3 - 3 =		x \$84.00	\$	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ 280.00	TOTAL OF ABOVE CALCULATIONS =				\$890	<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+	SUBTOTAL =				\$890	Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFT 1.492(f)).				\$	TOTAL NATIONAL FEE =				\$890	Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	TOTAL FEES ENCLOSED =				\$890					Amount to be refunded:	\$					charged:	\$																																																
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			\$																																																																																																															
Total claims	20 - 20 =		x \$18.00	\$																																																																																																																	
Independent claims	3 - 3 =		x \$84.00	\$																																																																																																																	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ 280.00																																																																																																																	
TOTAL OF ABOVE CALCULATIONS =				\$890																																																																																																																	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+																																																																																																																	
SUBTOTAL =				\$890																																																																																																																	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFT 1.492(f)).				\$																																																																																																																	
TOTAL NATIONAL FEE =				\$890																																																																																																																	
Fee for recording the enclosed assignment (37 CFR 1.2(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+																																																																																																																	
TOTAL FEES ENCLOSED =				\$890																																																																																																																	
				Amount to be refunded:	\$																																																																																																																
				charged:	\$																																																																																																																
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.																																																																																																																					
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 20-1430 in the amount of \$_____ to cover the above fees.																																																																																																																					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 20-1430 . A duplicate copy of this sheet is enclosed.																																																																																																																					
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.																																																																																																																					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.																																																																																																																					
SEND ALL CORRESPONDENCE TO:																																																																																																																					
Joe Liebeschuetz Townsend and Townsend and Crew LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111																																																																																																																					
<div style="display: flex; align-items: center;"> <div> SIGNATURE Joe Liebeschuetz NAME 37.505 REGISTRATION NUMBER </div> </div>																																																																																																																					

5040 PC/10
10/019832
1/30/2002

CRF Errors Corrected by the STIC Systems Branch

Serial Number: 10/019,832

CRF Processing Date: 1/30/2002
Edited by: [Signature]
Verified by: [Signature] (STIC staff)

ENTERED

☐ Changed a file from non-ASCII to ASCII

☐ Changed the margins in cases where the sequence text was "wrapped" down to the next line.

☐ Edited a format error in the Current Application Data section, specifically:

☐ Edited the Current Application Data section with the actual current number. The number inputted by the applicant was ☐ the prior application data; or ☐ other _____.

☐ Added the mandatory heading and subheadings for "Current Application Data".

☐ Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.

☐ Changed the spelling of a mandatory field (the headings or subheadings), specifically:

☐ Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were:

☐ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:

☐ Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.

☐ Inserted colons after headings/subheadings. Headings edited included:

☐ Deleted extra, invalid, headings used by an applicant, specifically:

☐ Deleted: ☒ non-ASCII "garbage" at the beginning/end of files; ☐ secretary initials/filename at end of file;
☐ page numbers throughout text; ☐ other invalid text, such as _____.

☐ Inserted mandatory headings, specifically:

☐ Corrected an obvious error in the response, specifically:

☐ Edited identifiers where upper case is used but lower case is required, or vice versa.

☐ Corrected an error in the Number of Sequences field, specifically:

☐ A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.

☐ Deleted **ending** stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: _____

☐ Other: _____

Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.

3/1/95



PCT10

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/019,832

DATE: 01/30/2002

TIME: 13:20:21

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF3\01302002\J019832.raw

```

3 <110> APPLICANT: Genox Research, Inc.
5 <120> TITLE OF INVENTION: POLLEN ALLERGY-RELATED GENE 513
7 <130> FILE REFERENCE: G1-103PCT
C--> 9 <140> CURRENT APPLICATION NUMBER: US/10/019,832
C--> 10 <141> CURRENT FILING DATE: 2001-10-26
12 <150> PRIOR APPLICATION NUMBER: JP 1999-120491
13 <151> PRIOR FILING DATE: 1999-04-27
15 <160> NUMBER OF SEQ ID NOS: 9
17 <170> SOFTWARE: PatentIn Ver. 2.0
19 <210> SEQ ID NO: 1
20 <211> LENGTH: 1171
21 <212> TYPE: DNA
22 <213> ORGANISM: Homo sapiens
24 <400> SEQUENCE: 1
25 actcactata gggctcgagc ggcgcccggg caggtatacc ttcggtgttt ttgagaatct 60
26 gagaatgatg gaggagaaat ggaaagatag gaatagaaag agattacatt aggaattaaa 120
27 tttcttggtc ctctttttct gatatgaaac caaattggag gttagatcat ccagaaagag 180
28 aattcagtggt tttccagttt tccaacctgc ttgctcataa gaatgacttg gagtggtaga 240
29 tottgattca gtcgtttotga ggatagcaca aagaatttgt attttttagca aacactctcc 300
30 atgattatag tattatatgg gaattaaact taaaccttct ttaaataaag cccccaagtt 360
31 tgaccocatta gctcagctat agaattactg aatattttta gtatggcaat actgtcaaga 420
32 aaaagcactt tataatgtgc ttaaatttct ttctttcctt tcctttcttt ctttctttct 480
33 ttctttcttt ctttctttct ttctttttg aaaagtttta ggctatataa aaaatagaga 540
34 gaatggggct tctcgctatg ctcagcctgt gtgtcatcat tactgtcatg ctggccattg 600
35 ttctctgctg ctgtgcccgg gccctgaggc ctccttcacc tctatcccca ccaccactat 660
36 ccagtcagtt tgcgtgctgt tccgtgggtc acatgaggca gatgaggagt ttgatgcatg 720
37 ctgggtgaca tgcttcaaca agccagagat agatgcctgg gaattgcata aagaattgaa 780
38 cacacttgct ggctatgacc tggttccaga accccaaatc attgatgttg cttcgcaggc 840
39 atgcagacag ttcgatgctt ttcttagggc agtttgcac ctagagggtt ttaaggacaa 900
40 ggcaggacct cataagaaaa tgtcatccaa gaactcagac caactttaaa tgaattggga 960
41 atccccactc cagaggacct aggccttagac aaagtgtgaa cccagggac aagcgttcca 1020
42 gggatttatt ggtattgcta cttgattgta aacactcccc tggaaatgct gatgataaca 1080
43 tgttacotta tttgaacacc tttttcttta ttgaataccw aaccatgtta tggtaacttg 1140
44 gactttaata aaagggaaat gagtttgaac t 1171
46 <210> SEQ ID NO: 2
47 <211> LENGTH: 17
48 <212> TYPE: DNA
49 <213> ORGANISM: Artificial Sequence
51 <220> FEATURE:
52 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
53 Synthesized Primer Sequence
55 <400> SEQUENCE: 2
56 gttttttttt tttttta

```

17

RAW SEQUENCE LISTING

DATE: 01/30/2002

PATENT APPLICATION: US/10/019,832

TIME: 13:20:21

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF3\01302002\J019832.raw

```

58 <210> SEQ ID NO: 3
59 <211> LENGTH: 17
60 <212> TYPE: DNA
61 <213> ORGANISM: Artificial Sequence
63 <220> FEATURE:
64 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
65     Synthesized Primer Sequence
67 <400> SEQUENCE: 3
68 gttttttttt ttttttc                                17
70 <210> SEQ ID NO: 4
71 <211> LENGTH: 17
72 <212> TYPE: DNA
73 <213> ORGANISM: Artificial Sequence
75 <220> FEATURE:
76 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
77     Synthesized Primer Sequence
79 <400> SEQUENCE: 4
80 gttttttttt ttttttg                                17
82 <210> SEQ ID NO: 5
83 <211> LENGTH: 10
84 <212> TYPE: DNA
85 <213> ORGANISM: Artificial Sequence
87 <220> FEATURE:
88 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
89     Synthesized Primer Sequence
91 <400> SEQUENCE: 5
92 tcatgcagac                                          10
94 <210> SEQ ID NO: 6
95 <211> LENGTH: 22
96 <212> TYPE: DNA
97 <213> ORGANISM: Artificial Sequence
99 <220> FEATURE:
100 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
101     Synthesized Primer Sequence
103 <400> SEQUENCE: 6
104 gcagacagtt cgatgctttt cc                          22
106 <210> SEQ ID NO: 7
107 <211> LENGTH: 23
108 <212> TYPE: DNA
109 <213> ORGANISM: Artificial Sequence
111 <220> FEATURE:
112 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
113     Synthesized Primer Sequence
115 <400> SEQUENCE: 7
116 ttttcttatg aggtcctgcc ttg                          23
118 <210> SEQ ID NO: 8
119 <211> LENGTH: 31
120 <212> TYPE: DNA
121 <213> ORGANISM: Artificial Sequence

```

RAW SEQUENCE LISTING

DATE: 01/30/2002

PATENT APPLICATION: US/10/019,832

TIME: 13:20:21

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF3\01302002\J019832.raw

123 <220> FEATURE:

124 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially

125 Synthesized Probe Sequence

127 <400> SEQUENCE: 8

128 agggcagttt gcatacctaaa gggttgtaag g 31

130 <210> SEQ ID NO: 9

131 <211> LENGTH: 23

132 <212> TYPE: DNA

133 <213> ORGANISM: Artificial Sequence

135 <220> FEATURE:

136 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially

137 Synthesized Primer Sequence

139 <400> SEQUENCE: 9

140 gcttgccct ggggttcaca ctt 23

DATE: 01/30/2002

TIME: 13:20:22

Input Set : A:\PTO.AMC.txt

Output Set: N:\CRF3\01302002\J019832.raw

L:9 M:270 C: Current Application Number differs, Replaced Application Number

L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date

[illegible]



PCT10

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/019,832

DATE: 01/24/2002

TIME: 13:16:22

Input Set : A:\sequence list in MS word.txt

Output Set: N:\CRF3\01242002\J019832.raw

**Does Not Comply
Corrected Diskette Needed**

3 <110> APPLICANT: Genox Research, Inc.
 5 <120> TITLE OF INVENTION: POLLEN ALLERGY-RELATED GENE 513
 7 <130> FILE REFERENCE: G1-103PCT
 9 <140> CURRENT APPLICATION NUMBER: US/10/019,832
 10 <141> CURRENT FILING DATE: 2001-10-26
 12 <150> PRIOR APPLICATION NUMBER: JP 1999-120491
 13 <151> PRIOR FILING DATE: 1999-04-27
 15 <160> NUMBER OF SEQ ID NOS: 9
 17 <170> SOFTWARE: PatentIn Ver. 2.0
 19 <210> SEQ ID NO: 1
 20 <211> LENGTH: 1171
 21 <212> TYPE: DNA
 22 <213> ORGANISM: Homo sapiens
 24 <400> SEQUENCE: 1
 25 actcactata gggctcgagc ggcgcccggg caggtataacc ttcggtgttt ttgagaatct 60
 26 gagaatgatg gaggagaaat ggaaagatag gaatagaaag agattacatt aggaattaaa 120
 27 ttctttgttc ctctttttct gatatgaaac caaattggag gttagatcat ccagaaagag 180
 28 aattcagtggt tttccagttt tccaacctgc ttgctcataa gaatgacttg gagtggtaga 240
 29 tcttgattca gtcgttctga ggatagcaca aagaatttgt attttttagca aacactctcc 300
 30 atgattatag tattatatgg gaattaaact taaaccttct ttaaataaag cccccaagtt 360
 31 tgacccatta gctcagctat agaattactg aatattttta gtatggcaat actgtcaaga 420
 32 aaaagcactt tataatgtgc ttaaatttct ttcttttctt tcttttcttt ctttctttct 480
 33 ttcttttctt ctttctttct ttcttttttg aaaagttaa ggctatataa aaaatagaga 540
 34 gaatggggct tctcgctatg ctcagcctgt gtgtcatcat tactgtcatg ctggccattg 600
 35 ttctotgctg ctgtgcccgg gccctgaggc ctcttcaacc tctatcccca ccaccactat 660
 36 ccagtcagtt tgetgctgct tccgtggttc acatgaggca gatgaggagt ttgatgcatg 720
 37 ctgggtgaca tgcttcaaca agccagagat agatgcctgg gaattgcata agaattgaa 780
 38 cacacttgct ggctatgacc tggttccaga accccaaatc attgatgttg cttegcaggc 840
 39 atgcagacag ttcgatgctt ttcttagggc agtttgcatc ctagagggtg ttaaggacaa 900
 40 ggcaggacct cataagaaaa tgtcatccaa gaactcagac caactttaaa tgaattggga 960
 41 atccccactc cagaggacct aggcttagac aaagtgtgaa ccccgaggac aagcgttcca 1020
 42 gggatttatt ggtattgcta cttgattgta aacactcccc tggaaatgct gatgataaca 1080
 43 tgttacctta tttgaacacc tttttcttta ttgaataccw aacctgttta tggtaacttg 1140
 44 gactttaata aaagggaaat gagtttgaac t 1171
 46 <210> SEQ ID NO: 2
 47 <211> LENGTH: 17
 48 <212> TYPE: DNA
 49 <213> ORGANISM: Artificial Sequence
 51 <220> FEATURE:
 52 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
 53 Synthesized Primer Sequence
 55 <400> SEQUENCE: 2
 56 gttttttttt tttttta

17

RAW SEQUENCE LISTING

DATE: 01/24/2002

PATENT APPLICATION: US/10/019,832

TIME: 13:16:22

Input Set : A:\sequence list in MS word.txt

Output Set: N:\CRF3\01242002\J019832.raw

```

58 <210> SEQ ID NO: 3
59 <211> LENGTH: 17
60 <212> TYPE: DNA
61 <213> ORGANISM: Artificial Sequence
63 <220> FEATURE:
64 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
65     Synthesized Primer Sequence
67 <400> SEQUENCE: 3
68 gttttttttt ttttttc                                17
70 <210> SEQ ID NO: 4
71 <211> LENGTH: 17
72 <212> TYPE: DNA
73 <213> ORGANISM: Artificial Sequence
75 <220> FEATURE:
76 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
77     Synthesized Primer Sequence
79 <400> SEQUENCE: 4
80 gttttttttt ttttttg                                17
82 <210> SEQ ID NO: 5
83 <211> LENGTH: 10
84 <212> TYPE: DNA
85 <213> ORGANISM: Artificial Sequence
87 <220> FEATURE:
88 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
89     Synthesized Primer Sequence
91 <400> SEQUENCE: 5
92 tcatgcagac                                         10
94 <210> SEQ ID NO: 6
95 <211> LENGTH: 22
96 <212> TYPE: DNA
97 <213> ORGANISM: Artificial Sequence
99 <220> FEATURE:
100 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
101     Synthesized Primer Sequence
103 <400> SEQUENCE: 6
104 gcagacagtt cgatgctttt cc                          22
106 <210> SEQ ID NO: 7
107 <211> LENGTH: 23
108 <212> TYPE: DNA
109 <213> ORGANISM: Artificial Sequence
111 <220> FEATURE:
112 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially
113     Synthesized Primer Sequence
115 <400> SEQUENCE: 7
116 ttttcttatg aggtcctgcc ttg                          23
118 <210> SEQ ID NO: 8
119 <211> LENGTH: 31
120 <212> TYPE: DNA
121 <213> ORGANISM: Artificial Sequence

```

RAW SEQUENCE LISTING

DATE: 01/24/2002

PATENT APPLICATION: US/10/019,832

TIME: 13:16:22

Input Set : A:\sequence list in MS word.txt

Output Set: N:\CRF3\01242002\J019832.raw

123 <220> FEATURE:

124 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially

125 Synthesized Probe Sequence

127 <400> SEQUENCE: 8

128 agggcagttt gcatcctaaa ggttggttaag g 31

130 <210> SEQ ID NO: 9

131 <211> LENGTH: 23

132 <212> TYPE: DNA

133 <213> ORGANISM: Artificial Sequence

135 <220> FEATURE:

136 <223> OTHER INFORMATION: Description of Artificial Sequence:Artificially

137 Synthesized Primer Sequence

139 <400> SEQUENCE: 9

140 gcttggtccct ggggttcaca ctt 23

W-- 145 ??

W-- 146 Footnote continued from previous page

W-- 148 Footnote continued on next page

W-- 150 3

delete

DATE: 01/24/2002

TIME: 13:16:23

Input Set : A:\sequence list in MS word.txt

Output Set: N:\CRF3\01242002\J019832.raw

```
L:9 M:270 C: Current Application Number differs, Replaced Application Number
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:145 M:334 W: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:1
L:146 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:9
L:146 M:334 W: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:5
L:148 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:9
L:148 M:334 W: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:5
L:150 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:9
```

10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

"Express Mail" Label No. EL525748597US

Date of Deposit October 26, 2001


PATENT

Attorney Docket No.: 082370000000

Client Ref. No.: G1-103PCT-US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

By: (Daniel Miranda) 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nagasu et al.

Application No.: Unassigned

Filed: October 26, 2001

For: POLLEN ALLERGY-RELATED
GENE 513

Art Unit:

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

IN THE CLAIMS:

Please amend claims 3, 4, 8, 9, 18, 19, and 20.

3. A DNA that specifically hybridizes to the nucleic acid molecule of claim 1 and that is at least 15 nucleotides long.

4. A method for detecting the nucleic acid molecule of claim 1, wherein said method uses DNA that hybridizes to SEQ ID NO:1.

8. The method of claim 5, wherein said T cells are prepared from

peripheral blood of said subject.

9. The method of claim 5, wherein said allergic disease is a cedar pollen allergy.

18. The method of claim 10, wherein said T cells are prepared from peripheral blood of said pollen allergy model animal.

19. The method of claim 12, wherein said lymphocytes are prepared from peripheral blood.


20. The method of claim 10, wherein said allergic disease is a cedar pollen allergy.

REMARKS

The claims have been amended to remove multi-dependency and thereby reduce filing fees.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400
Fax: (650) 326-2422
JOL:pfh
PA 3179426 v1

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claim 3 has been amended as follows:

3. A DNA that specifically hybridizes to the nucleic acid molecule of claim 1 ~~or 2~~ and that is at least 15 nucleotides long.

Claim 4 has been amended as follows:

4. A method for detecting the nucleic acid molecule of claim 1, wherein said method uses ~~the DNA of claim 3~~ DNA that hybridizes to SEQ ID NO:1.

Claim 8 has been amended as follows:

8. The method of ~~any one of~~ claims 5 ~~to 7~~, wherein said T cells are prepared from peripheral blood of said subject.

Claim 9 has been amended as follows:

9. The method of ~~any one of~~ claims 5 ~~to 8~~, wherein said allergic disease is a cedar pollen allergy.

Claim 18 has been amended as follows:

18. The method of claim 10 ~~or 11~~, wherein said T cells are prepared from peripheral blood of said pollen allergy model animal.

Claim 19 has been amended as follows:

19. The method of ~~any one of~~ claims 12 ~~to 15~~, wherein said lymphocytes are prepared from peripheral blood.

Claim 20 has been amended as follows:

20. The method of ~~any one of~~ claims 10 ~~to 19~~, wherein said allergic disease is a cedar pollen allergy.

PA 3179426 v1

4004963-103706

2/pts 1

DESCRIPTION

POLLEN ALLERGY-RELATED GENE 5135 Technical Field

The present invention relates to a gene involved in allergic disease, in particular, pollen allergy, and a method for testing for an allergic disease and a method for screening for a candidate compound for a therapeutic drug for an allergy using the expression of the gene as an index.

Background Art

Allergic diseases including pollen allergy are considered to be multifactorial diseases. These diseases involve the expression of many different genes each of which is influenced by various environmental factors. Thus, it is very difficult to identify a specific gene which causes a specific disease.

Additionally, allergic diseases are thought to involve the expression of mutated or defective genes, or overexpression or reduction of the specific gene expression. To elucidate the role of gene expression in diseases, it is necessary to understand how a gene is involved in triggering disease onset and how expression of the gene is altered by external stimulants such as drugs.

Recent developments in gene expression analysis techniques have made it possible to analyze and compare the gene expression of many clinical samples. Among these methods, the differential display (DD) method is significantly useful. The differential display method was originally developed by Liang and Pardee in 1992 (Science, 1992, 257:967-971). By using this method, one can screen several tens or more different samples at one time and it is possible to detect altered gene expression among the samples. By revealing alterations in gene expression due to mutation as well as time- and environment-dependent gene expression, it is expected to provide important information about disease-related genes. Such genes include those of which

expression is influenced by environmental factors.

Among allergic diseases, pollen allergy has recently become more common. It is considered that some genes whose expression is affected by pollen, one of the environmental factors, are involved in cause of pollen allergy. Based on this situation, it was hoped that genes involved in pollen allergy could be isolated.

Disclosure of the Invention

An objective of the present invention is to provide a gene involved in allergic disease, in particular, pollen allergy. Another objective of the invention is to provide a method for testing for an allergic disease and a method for screening for a candidate compound for a therapeutic drug for an allergy using the expression of the gene as an index.

According to the previously established techniques of the "Fluorescent DD method" (T. Ito et al. FEBS Letter 351:231-236, 1994), the inventors developed a new DD system that can analyze T-cell RNA samples prepared from multiple human blood samples. The inventors isolated T cells from blood samples of multiple subjects including pollen allergy patients before and after exposure to pollen dispersal and conducted screening for a gene showing differential expression between subjects showing different cedar pollen-specific IgE titers, or before and after pollen dispersal. The inventors thus isolated a novel gene (gene 513).

The inventors divided the subjects into those with a high IgE titer against cedar pollen (cedar pollen allergy diathesis group) and others (normal group) and measured the expression level of the isolated gene 513 between the two groups. The results showed that the gene expression level was significantly higher in the cedar pollen allergy diathesis group compared to the normal group. Based on these observations, the inventors found that the gene expression level can be used as an index to test for an allergic disease and to screen for candidate compounds for a therapeutic drug for allergic diseases.

Therefore, the present invention relates to a gene showing high expression in individuals having the allergy diathesis and a method for testing for an allergic disease and a method for screening for a candidate compound for a therapeutic drug for allergic diseases using the gene expression as an index. More specifically, the present invention relates to:

(1) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1;

(2) a nucleic acid molecule comprising the coding region of the nucleotide sequence of SEQ ID NO: 1;

(3) a DNA that specifically hybridizes to the nucleic acid molecule of (1) or (2) and that is at least 15 nucleotides long;

(4) a method for detecting the nucleic acid molecule of (1), wherein said method uses the DNA of (3);

(5) a method for testing for an allergic disease, said method comprising the steps of:

(a) preparing T cells from a subject,

(b) preparing an RNA sample from said T cells,

(c) conducting hybridization with said RNA sample using the DNA of (3) as probe, wherein said DNA is labeled, and

(d) measuring the amount of RNA that is derived from said subject and that hybridizes with said DNA and comparing said amount with a control (normal group);

(6) a method for testing for an allergic disease, said method comprising the steps of:

(a) preparing T cells from a subject,

(b) preparing an RNA sample from said T cells,

(c) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(d) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of (3) as primer, and

(e) comparing the amount of a DNA amplified by said PCR with a control (normal group);

(7) the method of (6), wherein said PCR is carried out by a PCR amplification monitoring method;

(8) the method of any one of (5) to (7), wherein said T cells

are prepared from peripheral blood of said subject;

(9) the method of any one of (5) to (8), wherein said allergic disease is a cedar pollen allergy;

(10) a method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) administering a test compound to a pollen allergy model animal and stimulating with pollen antigen,

(b) preparing T cells from said model animal,

(c) preparing an RNA sample from said T cells,

(d) conducting hybridization with said RNA sample using the DNA of (3) as probe, wherein said DNA is labeled,

(e) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and

(f) selecting a compound that reduces the amount of said RNA measured in (e), compared to a control (a case where said test compound is not administered);

(11) a method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) administering a test compound to a pollen allergy model animal and stimulating with pollen antigen,

(b) preparing T cells from said model animal,

(c) preparing an RNA sample from said T cells,

(d) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(e) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of (3) as primer, and

(f) selecting a compound that reduces the amount of said DNA amplified in (e), compared to a control (a case where said test compound is not administered);

(12) a method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) administering a test compound to a pollen allergy model animal,

(b) preparing lymphocytes from said model animal,
(c) stimulating said lymphocytes with pollen antigen,
(d) separating T cells from said lymphocytes stimulated with said antigen,

5 (e) preparing an RNA sample from said T cells,

(f) conducting hybridization with said RNA sample using the DNA of (3) as probe, wherein said DNA is labeled,

(g) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and

10 (h) selecting a compound that reduces the amount of said RNA measured in (g), compared to a control (a case where said test compound is not administered);

15 (13) a method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) administering a test compound to a pollen allergy model animal,

(b) preparing lymphocytes from said model animal,

(c) stimulating said lymphocytes with pollen antigen;

20 (d) separating T cells from said lymphocytes stimulated with said antigen,

(e) preparing an RNA sample from said T cells,

(f) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

25 (g) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of (3) as primer, and

(h) selecting a compound that reduces the amount of said DNA amplified in (g), compared to a control (a case where said test compound is not administered);

30 (14) a method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) preparing lymphocytes from a pollen allergy model animal or from a human having a pollen allergy,

35 (b) stimulating said lymphocytes with pollen antigen in the presence of a test compound,

(c) separating T cells from said lymphocytes stimulated with said antigen,

(d) preparing an RNA sample from said T cells,

(e) conducting hybridization with said RNA sample using the DNA of (3) as probe, wherein said DNA is labeled,

(f) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and

(g) selecting a compound that reduces the amount of said RNA measured in (f), compared to a control (a case where said test compound is not administered);

(15) a method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) preparing lymphocytes from a pollen allergy model animal or from a human having a pollen allergy,

(b) stimulating said lymphocytes with pollen antigen in the presence of a test compound,

(c) separating T cells from said lymphocytes stimulated with said antigen,

(d) preparing an RNA sample from said T cells,

(e) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(f) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of (3) as primer, and

(g) selecting a compound that reduces the amount of said DNA amplified in (f), compared to a control (a case where said test compound is not administered);

(16) a method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) stimulating a T-cell line with a lymphocyte-stimulating substance in the presence of a test compound,

(b) preparing an RNA sample from said stimulated T-cell line,

(c) conducting hybridization with said RNA sample using the DNA of (3) as probe, wherein said DNA is labeled,

(d) measuring the amount of RNA that is derived from said T-

cell line and that hybridizes with said DNA, and

(e) selecting a compound that reduces the amount of said RNA measured in (d), compared to a control (a case where said test compound is not administered);

5 (17) a method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) stimulating a T-cell line with a lymphocyte-stimulating substance in the presence of a test compound,

10 (b) preparing an RNA sample from said stimulated T-cell line,

(c) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(d) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of (3) as primer, and

15 (e) selecting a compound that reduces the amount of said DNA amplified in (d), compared to a control (a case where said test compound is not administered);

20 (18) the method of (10) or (11), wherein said T cells are prepared from peripheral blood of said pollen allergy model animal;

(19) the method of any one of (12) to (15), wherein said lymphocytes are prepared from peripheral blood; and

(20) the method of any one of (10) to (19), wherein said allergic disease is a cedar pollen allergy.

25 In the present invention allergic disease is a general term for diseases that involve allergic reactions. More specifically, for a disease to be considered allergic, the allergen there must be identified, there exists a strong correlation between exposure to the allergen and the onset of the pathological
30 change, and the pathological change has been proven to have an immunological mechanism. An immunological mechanism means that the T cells show an immune response to allergen stimulation. Representative allergic diseases are bronchial asthma, allergic rhinitis, atopic dermatitis, pollen allergy, insect allergy, etc.
35 Allergic diathesis is a genetic factor which is inherited from allergic parents to children. Familial allergic diseases are

also called atopic diseases, and their causative factor which can be inherited is atopic diathesis.

In the present invention, "nucleic acid molecule" includes DNA and RNA. Also in the present invention, "testing for an allergic disease" includes not only testing a patient who has been affected with the disease but also testing a subject who has not affected with the disease for whether the subject has an allergic diathesis or not.

The present invention relates to a novel gene 513 that correlates with IgE production response against cedar pollen in individuals. The nucleotide sequence of gene 513 cDNA which was found by the inventors is shown in SEQ ID NO: 1.

The nucleotide sequence of gene 513 cDNA which was isolated by the inventors is a partial sequence of 513 cDNA, but one skilled in the art can usually isolate the full length cDNA of gene 513, based on the sequence information of 513 cDNA described in SEQ ID NO: 1. Examples of methods for isolating the full length cDNA include a method for screening a T-cell cDNA library and such by hybridization using a gene 513-derived sequence as a probe and a method for obtaining the full length of the cDNA by screening libraries with an amplification product to be obtained having a primer-specific size as an index using gene 513-derived sequences as primers and using the T-cell cDNA library and such as a template. The examples further include a method for extending the sequence of gene 513 by the RACE method (Frohman, M. A. et al.: Proc. Natl. Acad. Sci. USA, 85: 8992, 1988), in which mRNAs of T cells and such are converted into single stranded cDNAs by using a gene 513-derived sequence as a primer, an oligomer is attached to the end of the cDNA thus obtained, and then PCR is carried out.

Herein, "nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1" includes the full length gene 513 cDNA which can be isolated from information of the 513 cDNA nucleotide sequence according to SEQ ID NO: 1.

Gene 513 expression was significantly higher in the atopic diathesis group (IgE titer against cedar pollen is 3.5 AU/ml or

more) than in the non-atopic diathesis group. Therefore, using gene 513 expression (including transcription to mRNA and translation to protein) as an index, it may be possible to test for an allergic disease and to screen for a candidate compound for a therapeutic drug for allergic diseases.

As a disease that can be a target for the testing and treatment in the present invention, cedar pollen allergy is particularly preferable.

Expression of gene 513 can be detected in testing for an allergic disease in the present invention by using a hybridization technique with nucleic acids which can hybridize with gene 513 as probes or by using a gene amplification technique with DNAs which can hybridize with the gene of the present invention as primers.

The probe or primer used for testing for a disease in the present invention means nucleic acid molecules which specifically hybridize to gene 513 and are at least 15 nucleotide long. Herein "specifically hybridize" means that under normal hybridization conditions, preferably stringent conditions, there is no significant cross hybridization with DNA and/or RNA encoding other genes. Stringent condition means, for example, carrying out hybridization using a probe and transfer membrane at 68°C in Express Hybridization Solution (CLONTECH) and a final wash of 0.1X SSC, 0.05% SDS at 50°C.

These nucleic acid molecules could be either synthetic or natural ones. Also, labeled DNA is usually used as the probe for hybridization. The labeling methods may be nick translation using DNA polymerase I, end labeling using polynucleotide kinase, fill-in end labeling using Klenow fragment (Berger SL, Kimmel AR. (1987) Guide to Molecular Cloning Techniques, Method in Enzymology, Academic Press; Hames BD, Higgins SJ (1985) Genes Probes: A Practical Approach. IRL Press; Sambrook J, Fritsch EF, Maniatis T. (1989) Molecular Cloning: a Laboratory Manual, 2nd Edn. Cold Spring Harbor Laboratory Press), transcription labeling using RNA polymerase (Melton DA, Krieg, PA, Rebagliati MR, Maniatis T, Zinn K, Green MR. (1984) Nucleic Acid Res., 12,

7035-7056), non-isotopic DNA labeling techniques by incorporating modified nucleotides (Kricka LJ. (1992) Nonisotopic DNA Probing Techniques. Academic Press), etc.

For testing for an allergic disease using hybridization techniques, for example, Northern hybridization, dot blot hybridization, or DNA micro array technique may be used.

As for gene amplification techniques, for example, RT-PCR may be used. Using the PCR amplification monitoring method during the gene amplification step in RT-PCR as described in Example 8, one can obtain a more accurate quantification of gene 513 expression.

In the PCR amplification monitoring method, the target (DNA or reverse transcribed product of RNA) is hybridized to probes that are dual-labeled at both ends with different fluorescent dyes which, in combination, cancel out their fluorescence each other. When the PCR proceeds and the 5'-3' exonuclease activity of Taq polymerase degrades the probe, the two fluorescent dyes become distant from each other and the fluorescence comes to be detected. The fluorescence is detected in real time. By simultaneously measuring for a standard sample in which the copy number of the target is known, it is possible to determine the copy number of the target in the subject sample with the cycle number where PCR amplification is linear (Holland, P.M. et al., 1991, Proc. Natl. Acad. Sci. USA 88:7276-7280; Livak, K. J. et al., 1995, PCR Methods and Applications 4(6):357-362; Heid, C. A. et al., Genome Research 6:986-994; Gibson, E. M. U. et al., 1996, Genome Research 6:995-1001). For the PCR amplification monitoring method, for example, ABI PRISM7700 (Perkin Elmer) may be used.

Testing for an allergic disease in the present invention can be also carried out by detecting a protein encoded by gene 513. For such testing methods, for example, Western blotting analysis, immunoprecipitation, or ELISA using antibody against the protein encoded by gene 513 may be used.

Antibodies against the protein encoded by the gene 513 of the present invention, may be produced as polyclonal or

monoclonal antibody by techniques known to one skilled in the art (Milstein C, et al., 1983, Nature 305(5934): 537-40). Protein or its partial peptide used as an antigen may be obtained, for example, by inserting gene 513 or its partial sequence into an expression vector, by introducing it into an appropriate host cell to prepare a transformant, by culturing the transformant to express the recombinant protein, and by purifying the expressed recombinant protein from the cultured transformant or the culture supernatant.

In testing for an allergic disease in the present invention, if expression of the gene of the invention is significantly higher in a subject, the subject may be determined to have allergic diathesis with high IgE titer against an allergen such as cedar pollen antigen. It is possible to use the expression level of the gene of the invention together with allergen specific antibody titer, symptoms, and such for testing for an allergic disease.

Expression of gene 513 in T cells is increased in the pollen allergy patient group, which shows high levels of pollen antigen specific IgE. Allergic patients who show response toward antigens except cedar pollen may also give high expression of gene 513 when the T-cell response is accelerated by the antigens. In such a case, increased expression of gene 513 corresponds to an acceleration of the T-cell response, and thus by monitoring the expression level of gene 513, it is possible to screen for therapeutic drugs for an allergic disease.

Methods for screening for a candidate compound for the treatment of allergic disease in this invention can be carried out *in vivo* or *in vitro*. In the *in vivo* screening, for example, model animals such as mice may be administered with a candidate agent and stimulated with pollen antigen. Then T cells are prepared from peripheral blood to measure the transcript product level of gene 513. Alternatively, after administering a candidate agent to model animals such as mice, lymphocytes are separated from peripheral blood and stimulated by cedar pollen antigen and such *in vitro*. After the stimulation, T cells are

prepared from the lymphocytes, and the transcript product level of gene 513 is measured. As a result of this measurement, a compound which can reduce transcription level of gene 513 may be selected. Here, the stimulation by pollen antigen is carried out to trigger an antigen-specific allergic response in T cells and to judge the treatment effect of the candidate compound on the response.

In an *in vitro* screening, for example, peripheral blood lymphocytes from a pollen-allergic person, mouse, and such are collected and stimulated by cedar pollen antigen *in vitro*. At the time of *in vitro* stimulation, a candidate compound is added. Then T cells are prepared from the stimulated peripheral blood lymphocytes, and the transcript product levels of gene 513 are measured. As a result of this measurement, a compound which can reduce transcription level of gene 513 may be selected.

For screening for a candidate compound for a therapeutic drug for an allergic disease in this invention, a T-cell line may be used. For example, a T-cell line such as the Molt4 or Jurkat T-cell line may be stimulated by a lymphocyte stimulating substance *in vitro*. As for the lymphocyte stimulating substance, for example, calcium ionophore (A23187), PMA, or phytohemagglutinin (PHA) may be used. At the time of *in vitro* stimulation, the candidate agent is added. Then the transcript product level of gene 513 is measured in the T-cell line. As a result of this measurement, a compound which can reduce transcription level of gene 513 may be selected.

Like testing for an allergic disease in the invention, expression of gene 513 can be detected in screening for a candidate compound for a therapeutic drug for an allergic disease by using a hybridization technique with nucleic acids which can hybridize with gene 513 as probes or by using a gene amplification technique with DNAs which can hybridize with the gene of the present invention as primers.

As for hybridization techniques, for example, Northern hybridization, dot blot hybridization, or DNA micro array technique may be used. As for gene amplification techniques,

for example, RT-PCR may be used. Using the PCR amplification monitoring method as described in Example 8 during the gene amplification step in RT-PCR, one can more accurately quantify the gene 513 expression.

5 Test compounds used in such screening include compound preparations synthesized by existing chemical methods such as steroid derivatives, compound preparations synthesized by combinatorial chemistry, extracts from animal or plant tissues, mixtures of multiple compounds such as microbial cultures and
10 their purified preparations.

The compound isolated by the method for screening for a candidate compound for a therapeutic drug for an allergic disease in this invention can be a candidate agent for improving the condition of individuals having allergic diathesis against
15 allergens such as pollen antigen.

When a compound isolated by the screening method of the present invention is used as a drug, it can be formulated by any known pharmaceutical manufacturing methods. For example, the compound is administered to patients with a pharmaceutically
20 acceptable carrier or medium (e.g. physiological saline, vegetable oil, suspending agent, surfactant, stabilizer, etc.). The drug can be administered via various routes, for example, percutaneously, intranasally, transbronchially, intramuscularly, intravenously, or orally, depending on the properties of the
25 compound. Dosage may vary depending on some factors, such as age, weight, condition of the patient and the administration method, but those skilled in the art can properly determine the suitable dosage.

30 Brief Description of the Drawings

Figure 1 shows cedar pollen specific IgE antibody titer from a total of 18 blood samples obtained from 10 subjects. The cedar pollen specific IgE antibody titer of each blood sample from subjects A to J (sample number 1 to 18) is indicated in
35 AU/ml. The specific IgE antibody titers in blood samples prepared before (white column, left) and after (black column,

right) the dispersal of pollen are depicted in paired columns. Blood samples of subjects A and B were collected only after pollen dispersal.

Figure 2 shows the expression changes of gene 513 between a high IgE group and a normal IgE group that are grouped according to cedar pollen specific IgE titers. Error bars indicate standard deviation.

Best Mode for Carrying out the Invention

The present invention will be explained in detail below with reference to examples, but is not to be construed as being limited thereto.

Example 1. Blood sample collection from 10 adult volunteers

To collect T cells before and after cedar pollen dispersal, 10 ml blood samples were collected from 10 adult volunteers (A to J) before and after exposure to cedar pollen dispersal. The first blood sample was obtained before the Japanese cedar pollen dispersal season (January and February, 1997), and the second sampling time was after the Japanese cedar pollen dispersal season (March, April, and May, 1997). From eight people among the volunteers, blood samples were obtained at both periods. From two other people, samples could be obtained only after pollen dispersal season. Parts of the blood samples were used for measuring cedar pollen specific IgE amounts. For the specific IgE measurement, the CAP RAST method (Pharmacia) was employed, which is a modified RAST (radio allerge sorbent test, Wide, L. et, al.: Lancet 2: 1105-1107, 1967) method that uses a paper disk as a solid phase. Serum from Pharmacia which has standard antibody titer was used as the standard to determine the IgE antibody titer in the samples [unit was shown in either Pharmacia RAST Unit, PRU or AU (arbitrary unit)].

The cedar pollen specific IgE titers from each subject before and after pollen dispersal are shown in Fig. 1. As the figure indicates, the majority of the 10 subjects showed increases in the concentration of cedar pollen specific IgE in

sera after pollen exposure. A CAP RAST test value of cedar pollen specific IgE larger than 2 was used in judging whether a subject had or did not have atopic diathesis. Eight subjects, A to G and I, fell into the atopic diathesis group (will also be called "patient"), and subjects H and J were grouped as healthy (will also be called "normal"). Among the eight in the atopic diathesis group, seven showed allergic rhinitis after pollen dispersal.

Example 2. Preparation of lymphocyte fractions from blood samples

T cells were prepared from 10 ml of blood sample as follows. First, 1 ml of heparin (purchased from Novo or other company) was spread over the syringe wall surface, and then 10 ml of blood sample including a final concentration of 50 units/ml heparin was taken. For blood collection, two 22G needles for each person were prepared. After removing the needle from the syringe, the blood sample was transferred to a 50-ml centrifuge tube (polypropylene). The tube was centrifuged at 1500 rpm for 5 min at room temperature and then 1.1 ml was taken from as close to the surface as possible. After further 15000 rpm centrifugation for 5 min at 4°C, 1 ml of the supernatant was collected as plasma. An equal amount (9 ml) of 0.9% NaCl containing 3% dextran (Nacalai) was added to the remaining sample. This mixture was inverted gently several times, and then let stand for 30 min at room temperature. PRP (platelet rich plasma) was transferred to a new 15 ml centrifuge tube and centrifuged at 1200 rpm (equivalent to 150x g for the Tomy centrifuge) for 5 min at room temperature. After the centrifugation, platelets were present in the supernatant. Precipitated cells were resuspended in 5 ml of Ca, Mg free HBSS (GIBCO, etc.). The cell suspension was layered on the top of a 5 ml Ficoll Paque (Pharmacia)-containing Falcon tube (2006 or 2059, polypropylene) by use of a capillary pipette. After centrifuging the tube at 1200 rpm for 5 min, it was further centrifuged at 1500 rpm (equivalent to 400x g for the Tomy

centrifuge) for 30 min at room temperature. As a result, granulocytes and erythrocytes were precipitated, and lymphocytes, monocytes, and platelets were included in the middle layer, with the Ficoll layer between the precipitate and the middle layer.

5 The middle layer was collected by a capillary pipette. Two to three volumes of BSA/PBS (0.5% BSA, 2 mM EDTA in PBS, pH 7.2, degassed just before use) were added thereto, and the mixture was centrifuged at 1200 rpm for 5 min at 4°C. The precipitate was collected and washed twice with a BSA/PBS solution. After the second wash, cells were resuspended in 5 ml BSA/PBS, and a portion of the suspension was diluted two-fold with trypan blue to count the cell number. Total cell numbers were about 1×10^7 , and the suspension was used as lymphocyte fraction.

15 Example 3. T cell preparation from the lymphocyte fraction

The lymphocyte fraction obtained in Example 2 was centrifuged at 1200 rpm for 5 min at 4°C, and the precipitate was resuspended to 10^8 cells/100 μ l with BSA/PBS. The volume was approximately 20 μ l. The cell suspension was transferred to an Eppendorf tube (1.5 ml), and then a CD3 microbead solution was added thereto. This sample was allowed to stand at 4 to 10°C for 30 min (not on ice) and further treated using magnetic cell sorter (MACS, Miltenyi Biotech Inc.) by the following procedure.

25 An MS^+/RS^+ column was set to Mini MACS or Vario MACS separation unit (without needle). Five hundred μ l of BSA/PBS was gently applied onto the column, and the buffer was run off. Then CD3 microbead-labeled cells were applied onto the column. The column was washed three times using 500 μ l of BSA/PBS (B-cell fraction). The column was removed from the separation unit and set onto a tube to collect the eluate. One ml of BSA/PBS was applied onto the column, and CD3-positive cells were eluted rapidly using plunger attached with the column. This was used as T-cell fraction.

35 The obtained T-cell fraction was centrifuged at 1200 rpm at 4°C for 5 min. The precipitate was washed twice with BSA/PBS. After the second wash, the cells were resuspended in 1 ml of

BSA/PBS, and a portion of the suspension was diluted two-fold by trypan blue to count the cell number. Total cell numbers were approximately 4×10^6 .

5 Example 4. Total RNA preparation from the T cells

40 Total RNA was prepared from T cells using RNeasy Mini (Qiagen) basically following the manufactures' procedures. All the procedures were carried out at room temperature, wearing gloves. Four-fold volume of ethanol was added to wash buffer RPE. To the lysis buffer RLT, 10 μ l/ml of 2-mercaptoethanol was added. The cell suspension was centrifuged at 1000 to 1200 rpm for 5 min, and the supernatant was removed by aspiration. The precipitate was resuspended in 350 μ l lysis buffer RLT (with 2-mercaptoethanol). At this step, the cell lysate in the lysis buffer could be stored at -70°C . When the cell lysate was stored frozen, the lysate could be thawed by incubation at 37°C for 10 to 15 min and, if insoluble matter was observed, centrifuged for 3 min at maximum speed to collect only the supernatant. The lysate was homogenized by syringe with a 20G
15 Cathelin needle, and then 350- μ l lysate was applied onto QIAshredder by Pipetman and centrifuged at 1500 rpm for 2 min to collect eluate. Three hundred fifty μ l of 70% ethanol was added thereto and mixed well with pipetting. An RNeasy spin column was attached to the attached 2-ml tube, and the lysate mixture
20 was applied onto the column. The column was centrifuged at 8000x g (11500 rpm) for 1 min, and the flow through was discarded. Then 700 μ l of wash buffer RW1 was applied onto the column, and the column was let to stand for 5 min capped. The column was centrifuged at 11500 rpm for 15 seconds, and the flow
25 through was discarded. The column was set onto a new 2 ml tube, and 500 μ l of wash buffer RPE (containing ethanol) was applied onto the column. The column was then centrifuged at 11500 rpm for 15 sec, and the flow through was discard. Again 500 μ l of wash buffer RPE was applied onto the column and centrifuged at
30 full speed for 2 min. The column was transferred to a new tube (1.5 ml), 30 μ l of DEPC treated water was applied, and the

column was let to stand for 10 min capped. The column was centrifuged at 11500 rpm for 10 min to obtain total RNA. The concentration of the RNA was measured. If the amount was low, the column was set onto a new 1.5-ml tube again, 30 μ l of DEPC-treated water was applied, and the column was let to stand for 10 min capped and centrifuged at 11500 rpm for 10 min.

Example 5. DNase treatment of the total RNA

In order to remove DNA from the total RNA prepared from the T cells, DNase treatment was performed. The treatment was conducted in a reaction mixture containing 2 units of DNase (Nippon Gene) and 50 units of RNase inhibitor (Pharmacia) in 100 μ l of 1X DNase buffer (Nippon Gene). After incubating this at 37°C for 15 min, an equal volume of PCI (phenol:chloroform:isoamyl alcohol = 25:24:1) was added thereto, and the tube was vortexed. The tube was centrifuged at 12000 rpm at room temperature for 10 min, and the upper phase (water phase) was transferred to a new 1.5 ml tube. One tenth volume of 3 M sodium acetate (pH 5.2) and 2.5 volume of 100% ethanol with 1 μ l of Ethachinmate were added thereto, and the mixture was inverted several times. After allowing the tube to stand at -20°C for 15 min, it was centrifuged at 12000 rpm for 15 min at 4°C. The supernatant was removed, and 70% ethanol was added. After tapping the tube until the precipitate was detached from the tube, the supernatant was completely removed. The precipitate was dried for 3 min and dissolved in 10 to 20 μ l of DDW (DNase and RNase free). The concentration was measured, and the sample was stored at -80°C until use.

Example 6. Differential Display (DD) analysis using total RNA prepared from T cells

Fluorescent Differential Display (DD) analysis using total RNA prepared from T cells was carried out according to a reference (T. Ito et al., 1994, FEBS Letter. 351: 231-236). The total RNA prepared from the T cells was reverse transcribed to synthesize cDNA. For the first DD-PCR, 0.2 μ g total RNA served

as the template for three types of anchor primers to synthesize cDNA in separate reactions. For the second DD-PCR, 0.4 μg total RNA served as the template for three types of anchor primers to synthesize cDNA in separate reactions. In both case, the cDNAs were diluted to a final concentration equivalent to 0.4 ng/ μl RNA and used for further experiments. DD-PCR was carried out using the cDNA equivalent to 1 ng of the RNA per reaction. The reaction mixture composition was as shown in Table 1.

Table 1

cDNA (equivalent to 0.4 ng/ μl RNA)	2.5 μl
arbitrary primer (2 μM)	2.5 μl
10x AmpliTaq PCR buffer	1.0 μl
2.5 mM dNTP	0.8 μl
50 μM anchor primer (GT15A, GT15C, or GT15G)	0.1 μl
Gene Taq (5U/ μl)	0.05 μl
AmpliTaq (5U/ μl)	0.05 μl
dH ₂ O	3.0 μl
Total volume	10.0 μl

The PCR was carried out as follows: 1 cycle of 95°C for 3 min, 40°C for 5 min, and 72°C for 5 min; subsequently 30 cycles of 94°C for 15 sec, 40°C for 2 min, and 72°C for 1 min; after these cycles, 72°C for 5 min; and then continuously at 4°C.

For primer pairs, the anchor primer GT15A (SEQ NO ID: 2), GT15C (SEQ NO ID: 3), or GT15G (SEQ NO ID: 4), was used in combination with the arbitrary primers AG 1 to AG 110, AG 111 to AG 199, or AG 200 to AG 287, respectively, and a total of 287 combinations was tried. As for the arbitrary primers, oligomers having 10 nucleotide-long and a GC content of 50% were designed and synthesized.

For gel electrophoresis, a 6% denaturing polyacrylamide gel

was prepared, and 2.5 μ l of the sample from the PCR reaction was applied and run by 40 W for 210 min. After the electrophoresis, the gel was scanned by an Hitachi fluorescence imaging analyzer FMBIO II, and the gel image was obtained by detecting fluorescence.

Example 7. Amplification of a band obtained from DD analysis and its sequence determination

A large number of arbitrary primers were used to carry out DD analysis twice. Bands that differed between the patient and normal groups or blood samples before and after pollen dispersal were selected. Reproducible bands from two experiments were excised from the gels.

One of the excised bands (called 513) was further analyzed. Band 513 was found by a DD analysis using the anchor primer GT15C (SEQ ID NO: 3) and the arbitrary primer AG136 (TCATGCAGAC/SEQ ID NO: 5).

To determine the nucleotide sequence of 513, the gel containing band 513 was excised, and the DNA was eluted in a TE solution by heating at 60°C for 10 min. Using DNA dissolved in this TE solution as a template, PCR was conducted with the same condition as the original DD-PCR, and approximately 360 bp DNA fragment was amplified. In this PCR reaction, GT15C and AG136 were used as an anchor primer and arbitrary primer, respectively. The amplified DNA fragment was cloned into plasmid vector pCR2.1 (Invitrogen) to obtain the about 360 bp fragment harboring plasmid p513-122. The nucleotide sequence of the DNA fragment was determined using the plasmid with standard procedures.

Example 8. Quantification using ABI-7700

The expression level of 513 was quantified by TaqMan method using ABI-PRISM7700. This method enables quantification of PCR-amplified DNA strands in real-time using fluorescence dyes.

In order to carry out the quantification, blood samples from 22 new volunteers were collected before and after cedar pollen dispersal in the spring of 1998, and total RNAs were

extracted from T cells. Forty-four total RNA samples in total were used to quantify the expression of the target gene.

Using the same method as in Example 1, total IgE titer and specific IgE titers against cedar pollen, cypress pollen, and
5 the house-dust mites *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae* were measured as shown in Table 2.

Table 2

Specific IgE value

Subject	Time of blood collection	Specific IgE (UA/ml)				Total IgE (UA/ml)
		Cedar	Cypress	<i>Dermatophagoides pteronyssinus</i>	<i>Dermatophagoides farinae</i>	
A	Before dispersal	42.7	5.46	1.09	<0.34	300
	After dispersal	83.2	7.85	1.28	<0.34	460
B	Before dispersal	31.9	4.33	72.5	52.6	770
	After dispersal	36.8	3.56	78.8	47.9	840
C	Before dispersal	15.2	1.5	68.7	66.1	450
	After dispersal	20.3	1.32	64.3	49.7	330
D	Before dispersal	13.9	1.11	39.3	63.4	200
	After dispersal	18.4	0.81	31.9	54.7	120
E	Before dispersal	5.25	0.48	<0.34	<0.34	30
	After dispersal	8.33	0.46	<0.34	<0.34	38
F	Before dispersal	6.64	0.39	<0.34	<0.34	26
	After dispersal	8.21	0.47	<0.34	<0.34	27
G	Before dispersal	1.29	<0.34	<0.34	<0.34	26
	After dispersal	4.02	<0.34	<0.34	<0.34	30
H	Before dispersal	1.99	0.41	26.5	36.1	220
	After dispersal	3.65	0.53	23.2	29.5	150
I	Before dispersal	0.93	<0.34	54.6	51.7	130
	After dispersal	3.51	<0.34	43.3	39.9	100
J	Before dispersal	3.55	0.68	0.55	<0.34	96
	After dispersal	2.77	0.42	0.39	<0.34	78
K	Before dispersal	1.2	<0.34	<0.34	<0.34	96
	After dispersal	2.72	<0.34	<0.34	<0.34	110
L	Before dispersal	0.95	0.39	1.3	1.8	13
	After dispersal	2.5	0.51	1.45	2.38	18
M	Before dispersal	<0.34	<0.34	<0.34	<0.34	36
	After dispersal	2.08	<0.34	<0.34	<0.34	43
N	Before dispersal	0.42	<0.34	<0.34	<0.34	22
	After dispersal	1.67	<0.34	0.45	<0.34	73
O	Before dispersal	0.54	<0.34	28.1	27.2	180
	After dispersal	1.42	<0.34	27.2	26.3	160
P	Before dispersal	0.38	<0.34	5.08	3.65	280
	After dispersal	0.68	<0.34	4.49	3.02	240
Q	Before dispersal	<0.34	<0.34	<0.34	<0.34	<5.0
	After dispersal	<0.34	<0.34	<0.34	<0.34	<5.0
R	Before dispersal	<0.34	<0.34	<0.34	<0.34	53
	After dispersal	<0.34	<0.34	<0.34	<0.34	62
S	Before dispersal	<0.34	<0.34	<0.34	<0.34	420
	After dispersal	<0.34	<0.34	<0.34	<0.34	370
T	Before dispersal	<0.34	<0.34	<0.34	<0.34	82
	After dispersal	<0.34	<0.34	<0.34	<0.34	62
U	Before dispersal	<0.34	<0.34	<0.34	<0.34	18
	After dispersal	<0.34	<0.34	<0.34	<0.34	16
V	Before dispersal	<0.34	<0.34	0.79	0.81	180
	After dispersal	<0.34	<0.34	0.78	0.9	160

A DD band sequence determined in Example 7 was used to
 design and synthesize primers 513-TQ1
 (GCAGACAGTTCGATGCTTTTCC/SEQ ID NO: 6), 513-TQ2
 5 (TTTTCTTATGAGGTCCTGCCTTG/SEQ ID NO: 7), and TaqMan probe 513-TQM
 (AGGGCAGTTTGCATCCTAAAGGTTGTTAAGG/SEQ ID NO: 8) for use in the
 quantification reaction. TaqMan probe 513-TQM was labeled with
 fluorescence, FAM (6-carboxyfluorescein) and TAMRA (6-carboxy-
 tetramethyl-rhodamine) at 5'-end and 3'-end, respectively.
 10 cDNAs were used as templates which were prepared by reverse
 transcription from total RNAs of 44 samples using poly-T (12 to
 18 mer) as primers. To make a standard curve for the
 calculation of copy numbers, serial dilutions of plasmid p513-
 122 obtained in Example 7 was utilized as templates. The
 15 reaction mix composition for monitoring PCR amplification is
 shown in Table 3. To correct the difference in the cDNA
 concentrations between the samples, the same quantitative
 analysis was carried out for the β -actin gene, and its copy
 number was used to correct the copy number of the target gene
 20 513.

Table 3

Reaction mix composition for ABI-PRISM 7700 (per well)

5	Sterile distilled water	25.66 (μL)
	10x TaqMan buffer A	5
	25 mM MgCl_2	7
	dATP (10 mM)	1.2
	dCTP (10 mM)	1.2
10	dGTP (10 mM)	1.2
	dUTP (10 mM)	1.2
	Forward Primer (100 μM)	0.15
	Reverse Primer (100 μM)	0.15
	513 TaqMan probe (6.7 μM)	1.49
15	AmpliTaQ Gold (5U/ μL)	0.25
	AmpErase UNG (1U/ μL)	0.5
	Template solution	5
Total volume		50

20

The copy number of gene 513 in each of the samples corrected with β -actin copy number is shown in Table 4. The correction was performed by calculating average copy number of β -actin from all the samples and by dividing the copy number of gene 513 in each sample by the relative value of the copy number of β -actin in each sample when the average copy number was set at 1.

25

30

Table 4
 Quantification of data by ABI7700 (copy/ng RNA)
 Data corrected with beta-actin

Subject	Time of blood collection	Band ID
		513
A	Before dispersal	661
	After dispersal	871
B	Before dispersal	2880
	After dispersal	640
C	Before dispersal	530
	After dispersal	403
D	Before dispersal	1273
	After dispersal	433
E	Before dispersal	636
	After dispersal	692
F	Before dispersal	665
	After dispersal	1391
G	Before dispersal	692
	After dispersal	350
H	Before dispersal	1137
	After dispersal	361
I	Before dispersal	1169
	After dispersal	1717
J	Before dispersal	1846
	After dispersal	891
K	Before dispersal	443
	After dispersal	1007
L	Before dispersal	1742
	After dispersal	539
M	Before dispersal	721
	After dispersal	440
N	Before dispersal	459
	After dispersal	342
O	Before dispersal	662
	After dispersal	455
P	Before dispersal	409
	After dispersal	472
Q	Before dispersal	542
	After dispersal	662
R	Before dispersal	422
	After dispersal	25
S	Before dispersal	435
	After dispersal	332
T	Before dispersal	610
	After dispersal	449
U	Before dispersal	687
	After dispersal	455
V	Before dispersal	679
	After dispersal	368

A two-way layout analysis of variance was conducted using these data. The test was carried out according to the two factors: (1) before and after pollen dispersal and (2) the group that showed 3.5 AU/ml or more at least once in two measurements of each specific IgE in the sera (the high IgE group) and the other group (the normal IgE group). The number of subjects in each group was, for example, in the case of cedar pollen, 10 people in the high IgE group and 12 people in the normal IgE group. Another test was carried out for total IgE using the group that showed 200 AU/ml and the other group. A two-way layout analysis of variance was performed using StatView software (Abacus Concepts, Inc.).

As a result, when the IgE titer was grouped against cedar pollen, a significantly higher level of gene 513 expression was seen in the high IgE group compared to the normal IgE group (Table 5 and Fig. 2). When this result was combined with the IgE data obtained before and after pollen dispersal, the expression level of gene 513 in the high IgE group and the normal IgE group were 961.8 ± 626.1 and 556.7 ± 311.8 copies/ng RNA (average \pm standard deviation), respectively.

Table 5

513

Classification		Two-way layout analysis of variance P value		
		IgE high/low	Before dispersal/ after dispersal	Interaction of two factors
Specific IgE	Cedar	0.0100	0.0663	0.5189
	Cypress	0.0408	0.0518	0.0907
	<i>Dermatophagoides pteronyssinus</i>	0.2043	0.0606	0.2496
	<i>Dermatophagoides farinae</i>	0.2043	0.0606	0.2496
Total IgE		0.7893	0.0582	0.1872
t-test		0.0622		

Example 9. Cloning of gene 513 and nucleotide sequence analysis

Gene 513 was cloned using a Marathon cDNA Amplification Kit (CLONTECH). mRNAs of YY-1 cell line were used to synthesize cDNA to be used as templates for the Marathon kit. According to

the 513 nucleotide sequence isolated by DD analysis, specific primer 513_154L (GCTTGTCCTGGGGTTCACACTT/SEQ ID NO: 9) was designed to use with the adapter primer attached to the kit. The PCR was carried out, and up to approximately 1.1-kb amplification products were amplified. The nucleotide sequence of the fragment was found to be 1171 bp and contained the previously determined sequence. This sequence is shown as SEQ ID NO: 1.

Industrial Applicability

The present invention provided a novel gene that correlates with cedar pollen specific IgE titer. Using the expression of the gene of the present invention as an index, it is possible to test for whether a subject has an allergic diathesis or not, and to screen for a candidate compound for a therapeutic drug for a allergic disease.

CLAIMS

1. A nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1.
- 5 2. A nucleic acid molecule comprising the coding region of the nucleotide sequence of SEQ ID NO: 1.
3. A DNA that specifically hybridizes to the nucleic acid molecule of claim 1 or 2 and that is at least 15 nucleotides long.
- 10 4. A method for detecting the nucleic acid molecule of claim 1, wherein said method uses the DNA of claim 3.
- 15 5. A method for testing for an allergic disease, said method comprising the steps of:
 - (a) preparing T cells from a subject,
 - (b) preparing an RNA sample from said T cells,
 - (c) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled, and
 - (d) measuring the amount of RNA that is derived from said subject and that hybridizes with said DNA and comparing said amount with a control (normal group).
- 20 6. A method for testing for an allergic disease, said method comprising the steps of:
 - (a) preparing T cells from a subject,
 - (b) preparing an RNA sample from said T cells,
 - 25 (c) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,
 - (d) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and
 - (e) comparing the amount of a DNA amplified by said PCR with a control (normal group).
- 30 7. The method of claim 6, wherein said PCR is carried out by a PCR amplification monitoring method.
8. The method of any one of claims 5 to 7, wherein said T cells are prepared from peripheral blood of said subject.
- 35 9. The method of any one of claims 5 to 8, wherein said allergic disease is a cedar pollen allergy.

10. A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

- (a) administering a test compound to a pollen allergy model animal and stimulating with pollen antigen,
- (b) preparing T cells from said model animal,
- (c) preparing an RNA sample from said T cells,
- (d) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled,
- (e) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and
- (f) selecting a compound that reduces the amount of said RNA measured in (e), compared to a control (a case where said test compound is not administered).

11. A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

- (a) administering a test compound to a pollen allergy model animal and stimulating with pollen antigen,
- (b) preparing T cells from said model animal,
- (c) preparing an RNA sample from said T cells,
- (d) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,
- (e) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and
- (f) selecting a compound that reduces the amount of said DNA amplified in (e), compared to a control (a case where said test compound is not administered).

12. A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

- (a) administering a test compound to a pollen allergy model animal,
- (b) preparing lymphocytes from said model animal,
- (c) stimulating said lymphocytes with pollen antigen,
- (d) separating T cells from said lymphocytes stimulated with

said antigen,

(e) preparing an RNA sample from said T cells,

(f) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled,

5 (g) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and

(h) selecting a compound that reduces the amount of said RNA measured in (g), compared to a control (a case where said test compound is not administered).

10 13. A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) administering a test compound to a pollen allergy model animal,

15 (b) preparing lymphocytes from said model animal,

(c) stimulating said lymphocytes with pollen antigen;

(d) separating T cells from said lymphocytes stimulated with said antigen,

(e) preparing an RNA sample from said T cells,

20 (f) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

(g) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and

25 (h) selecting a compound that reduces the amount of said DNA amplified in (g), compared to a control (a case where said test compound is not administered).

14. A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

30 (a) preparing lymphocytes from a pollen allergy model animal or from a human having a pollen allergy,

(b) stimulating said lymphocytes with pollen antigen in the presence of a test compound,

35 (c) separating T cells from said lymphocytes stimulated with said antigen,

(d) preparing an RNA sample from said T cells,

(e) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled,

(f) measuring the amount of RNA that is derived from said T cells and that hybridizes with said DNA, and

5 (g) selecting a compound that reduces the amount of said RNA measured in (f), compared to a control (a case where said test compound is not administered).

15. A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) preparing lymphocytes from a pollen allergy model animal or from a human having a pollen allergy,

(b) stimulating said lymphocytes with pollen antigen in the presence of a test compound,

15 (c) separating T cells from said lymphocytes stimulated with said antigen,

(d) preparing an RNA sample from said T cells,

(e) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,

20 (f) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and

(g) selecting a compound that reduces the amount of said DNA amplified in (f), compared to a control (a case where said test compound is not administered).

25 16. A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:

(a) stimulating a T-cell line with a lymphocyte-stimulating substance in the presence of a test compound,

30 (b) preparing an RNA sample from said stimulated T-cell line,

(c) conducting hybridization with said RNA sample using the DNA of claim 3 as probe, wherein said DNA is labeled,

(d) measuring the amount of RNA that is derived from said T-cell line and that hybridizes with said DNA, and

35 (e) selecting a compound that reduces the amount of said RNA measured in (d), compared to a control (a case where said test

compound is not administered).

17. A method for screening for a candidate compound for a therapeutic drug for an allergic disease, said method comprising the steps of:


- 5 (a) stimulating a T-cell line with a lymphocyte-stimulating substance in the presence of a test compound,
- (b) preparing an RNA sample from said stimulated T-cell line,
- (c) synthesizing cDNA by conducting reverse transcription reaction with said RNA sample,
- 10 (d) conducting polymerase chain reaction (PCR) using said cDNA as template and the DNA of claim 3 as primer, and
- (e) selecting a compound that reduces the amount of said DNA amplified in (d), compared to a control (a case where said test compound is not administered).
- 15 18. The method of claim 10 or 11, wherein said T cells are prepared from peripheral blood of said pollen allergy model animal.
19. The method of any one of claims 12 to 15, wherein said lymphocytes are prepared from peripheral blood.
- 20 20. The method of any one of claims 10 to 19, wherein said allergic disease is a cedar pollen allergy.

ABSTRACT

5 T cells from multiple subjects who showed different cedar pollen specific IgE titers were prepared before and after cedar pollen dispersal, and differential display analysis was performed to screen for pollen antigen responsive genes. As a result, a novel gene was successfully isolated whose expression is significantly higher in subjects with high cedar pollen specific IgE titer. The inventors have found that it is possible to use this gene to test for an allergic disease and to screen for candidate compounds for therapeutic drugs for an allergic disease.


1 / 2

Figure 1



2 / 2

Figure 2



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **POLLEN ALLERGY-RELATED GENE 513** was filed as US National Phase of PCT/JP00/02733, filed April 26, 2000.

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
Japan	11/120491	April 27, 1999	Yes

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
PCT/JP00/02733	April 26, 2000	Pending

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.












Joe Liebeschuetz, Reg. No. 37,505
William M. Smith, Reg. No. 30,223
Rosemarie L. Celli, Reg. No. 42,397

Send Correspondence to: Joe Liebeschuetz TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834	Direct Telephone Calls to: (Name, Reg. No., Telephone No.) Name: Joe Liebeschuetz Reg. No.: 37,505 Telephone: 650-326-2400
---	--

Full Name of Inventor 1: 1-20	Last Name: NAGASU	First Name: TAKESHI	Middle Name or Initial:	
Residence & Citizenship:	City: Ibaraki	State/Foreign Country: Japan SPX	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: c/o Eisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3, Tokodai, Tsukuba-shi	City: Ibaraki	State/Country: Japan	Postal Code: 300-2635
Full Name of Inventor 2: 2-20	Last Name: SUGITA	First Name: YUJI	Middle Name or Initial:	
Residence & Citizenship:	City: Kanagawa	State/Foreign Country: Japan SPX	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: c/o Genox Research, Inc., Teikyo University Biotech Center, 907, Nogawa, Miyamae-ku, Kawasaki-shi	City: Kanagawa	State/Country: Japan	Postal Code: 216-0001
Full Name of Inventor 3: 3-20	Last Name: FUJISHIMA	First Name: TOMOKO	Middle Name or Initial:	
Residence & Citizenship:	City: Tokyo	State/Foreign Country: Japan SPX	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: c/o Kirin Brewery Company, Ltd., Pharmaceutical Division, 6-26-1, Jingumae, Shibuya-ku	City: Tokyo	State/Country: Japan	Postal Code: 150-8011
Full Name of Inventor 4: 4-20	Last Name: OSHIDA	First Name: TADAHIRO	Middle Name or Initial:	
Residence & Citizenship:	City: Kanagawa	State/Foreign Country: Japan SPX	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: c/o Genox Research, Inc., Teikyo University Biotech Center, 907, Nogawa, Miyamae-ku, Kawasaki-shi	City: Kanagawa	State/Country: Japan	Postal Code: 216-0001
Full Name of Inventor 5: 5-20	Last Name: OBAYASHI	First Name: MASAYA	Middle Name or Initial:	
Residence & Citizenship:	City: Tokyo	State/Foreign Country: Japan SPX	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: c/o Kyowa Hakko Kogyo Co., Ltd., Tokyo Research Laboratories, 3-6-6, Asahi-machi, Machida-shi	City: Tokyo	State/Country: Japan	Postal Code: 194-8533
Full Name of Inventor 6: 6-20	Last Name: GUNJI	First Name: SHIGEMICHI	Middle Name or Initial:	
Residence & Citizenship:	City: Tokyo	State/Foreign Country: Japan SPX	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: c/o Sankyo Co., Ltd., Department for Clinical Research, 7-12, Ginza 2-chome, Chuo-ku	City: Tokyo	State/Country: Japan	Postal Code: 104-8113

Full Name of Inventor 7:	Last Name: OBYASHI	First Name: IZUMI	Middle Name or Initial:	
Residence & Citizenship:	City: Kanagawa	State/Foreign Country: Japan	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: B-505, Luxage Aoba-Yamanote-Dai, 1-1, Nara 4-chome, Aoba-ku, Yokohama-shi	City: Kanagawa	State/Country: Japan	Postal Code: 227-0038
Full Name of Inventor 8:	Last Name: IMAI	First Name: YUKIHO	Middle Name or Initial:	
Residence & Citizenship:	City: Kanagawa	State/Foreign Country: Japan	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: c/o Genox Research, Inc., Teikyo University Biotech Center, 907, Nogawa, Miyamae-ku, Kawasaki-shi	City: Kanagawa	State/Country: Japan	Postal Code: 216-0001
Full Name of Inventor 9:	Last Name: YOSHIDA	First Name: NEI	Middle Name or Initial:	
Residence & Citizenship:	City: Kanagawa	State/Foreign Country: Japan	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: c/o Genox Research, Inc., Teikyo University Biotech Center, 907, Nogawa, Miyamae-ku, Kawasaki-shi	City: Kanagawa	State/Country: Japan	Postal Code: 216-0001
Full Name of Inventor 10:	Last Name: OGAWA	First Name: KAORU	Middle Name or Initial:	
Residence & Citizenship:	City: Kanagawa	State/Foreign Country: Japan	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: c/o Genox Research, Inc., Teikyo University Biotech Center, 907, Nogawa, Miyamae-ku, Kawasaki-shi	City: Kanagawa	State/Country: Japan	Postal Code: 216-0001
Full Name of Inventor 11:	Last Name: MATSUI	First Name: KEIKO	Middle Name or Initial:	
Residence & Citizenship:	City: Kanagawa	State/Foreign Country: Japan	Country of Citizenship: Japan	
Post Office Address:	Post Office Address: c/o Genox Research, Inc., Teikyo University Biotech Center, 907, Nogawa, Miyamae-ku, Kawasaki-shi	City: Kanagawa	State/Country: Japan	Postal Code: 216-0001

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  Takeshi NAGASU Date Jan/22/2002	Signature of Inventor 2  Yuji SUGITA Date Jan. 28/2002	Signature of Inventor 3  Tomoko FUJISHIMA Date Jan. 25, 2002
Signature of Inventor 4  Tadahiro OSHIDA Date Jan/28/2002	Signature of Inventor 5  Masaya OBAYASHI Date Jan. 17, 2002	Signature of Inventor 6  Shigemichi GUNJI Date Jan. 12, 2002
Signature of Inventor 7  Izumi OBAYASHI Date Jan. 17. 2002	Signature of Inventor 8  Yukiho IMAI Date Jan. 28. 2002	Signature of Inventor 9  Nei YOSHIDA Date Jan. 28. 2002
Signature of Inventor 10  Kaoru OGAWA Date Jan 28, 2002	Signature of Inventor 11  Keiko MATSUI Date Jan. 28. 2002	

1/6

SEQUENCE LISTING

<110> Genox Research, Inc.

<120> POLLEN ALLERGY-RELATED GENE 513

<130> G1-103PCT

<140>

<141>

<150> JP 1999-120491

<151> 1999-04-27

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 1171

<212> DNA

<213> Homo sapiens

<400> 1

actcactata gggctcgagc ggcgcccggg caggtataacc ttcggtgttt ttgagaatct 60

gagaatgatg gaggagaaat ggaaagatag gaatagaaag agattacatt aggaattaaa 120
 tttcttggtc ctctttttct gatatgaaac caaatggag gttagatcat ccagaaagag 180
 aattcagtgt tttccagttt tccaacctgc ttgctcataa gaatgacttg gagtggtaga 240
 tcttgattca gtcgttctga ggatagcaca aagaatttgt atttttagca aacactctcc 300
 atgattatag tattatatgg gaattaaact taaaccttct ttaaataaag cccccaagtt 360
 tgaccatta gtcagctat agaattactg aatattttta gtatggcaat actgtcaaga 420
 aaaagcactt tataatgtgc ttaaatttct ttctttcctt tcctttcttt ctttctttct 480
 ttctttcttt ctttctttct ttctttttgg aaaagtttaa ggctatataa aaaatagaga 540
 gaatggggct tctcgctatg ctccagctgt gtgtcatcat tactgtcatg ctggccattg 600
 ttctctgtcg ctgtgccgg gccctgagge ctcttcacc tctatcccca ccaccactat 660
 ccagtcagtt tgctgctgct tccgtgggtc acatgaggca gatgaggagt ttgatgcatg 720
 ctgggtgaca tgcttcaaca agccagagat agatgcctgg gaattgcata aagaattgaa 780
 cacacttgct ggctatgacc tggttccaga accccaaatc attgatgttg cttcgcagge 840
 atgcagacag ttcgatgctt ttccatgggc agtttgcac ctagaggttg ttaaggacaa 900
 ggcaggacct cataagaaaa tgtcatcaa gaactcagac caactttaaa tgaattggga 960
 atccccactc cagaggacct aggcttagac aaagtgtgaa cccagggac aagcgttcca 1020
 gggatttatt ggtattgcta cttgattgta aacactcccc tggaaatgct gatgataaca 1080
 tgttacctta ttgaacacc tttttcttta ttgaataccw aaccatgta tggttaactg 1140
 gactttaata aaagggaat gagtttgaac t 1171

<210> 2

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially
Synthesized Primer Sequence

<400> 2

gttttttttt tttttta

17

<210> 3

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially
Synthesized Primer Sequence

<400> 3

gttttttttt ttttttc

17

<210> 4

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially
Synthesized Primer Sequence

<400> 4

gttttttttt ttttttg

17

<210> 5

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially
Synthesized Primer Sequence

<400> 5

tcatgcagac

10

<210> 6

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially

Synthesized Primer Sequence

<400> 6

gcagacagtt cgatgctttt cc

22

<210> 7

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially
Synthesized Primer Sequence

<400> 7

ttttcttatg aggtcctgcc ttg

23

<210> 8

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially
Synthesized Probe Sequence

<400> 8

agggcagttt gcacctaataa ggttgtaag g

31

<210> 9

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Artificially

Synthesized Primer Sequence

<400> 9

gcttgccct ggggttcaca ctt

23